Accueil   Diary - News   All news ERYTECH ENGAGES IN COLLABORATIVE PARTNERSHIP WITH EU HORIZON 2020 EVIDENCE CONSORTIUM

ERYTECH ENGAGES IN COLLABORATIVE PARTNERSHIP WITH EU HORIZON 2020 EVIDENCE CONSORTIUM

 

 

LYON, France and CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENCE, a public-private consortium supported by the European Union in the framework of the EU Horizon 2020 program.

 


The EVIDENCE consortium, consisting of leading experts in the field of red blood cell research, will explore how red blood cells are influenced by their extra-cellular environment. This is an important aspect for the development of red blood cell-based therapies. The EVIDENCE consortium will investigate the behavior of red blood cells under physiological flow conditions, i.e. under conditions that are as close to reality as possible, to gain a better understanding of diseases and to develop improved diagnostic techniques and devices.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree